Evidence map›Paper›PMID 24819885›Full record

SynthesisEuropean journal of pediatrics2014

The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence.

Magdalena Urbańska, Hania Szajewska

Registry-linked trialAbstract readSystematic Review
In one paragraph

Synthesis in European journal of pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04847960 (The Effect of Probiotic Lactobacillus Reuteri Prodentis Consumption on Gingival Crevicular Fluid Inflammatory Response and Metagenomic Profiles of Oral Microbiome in Orthodontic Patients.), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04847960 naunknown statusnot on this mapstarted 2021, after this paper: background citation

The Effect of Probiotic Lactobacillus Reuteri Prodentis Consumption on Gingival Crevicular Fluid Inflammatory Response and Metagenomic Profiles of Oral Microbiome in Orthodontic Patients.

TypeinterventionalSponsorTrisakti UniversityRan2021 to 2023Enrolled20ConditionsHealthy Subjects With Fixed OrthodonticsArmsBioGaia Probiotic Lozenges
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. The Efficacy of the Administration ofAdvanced biomedical research · 2026
    Article
  7. Microorganisms · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Nutrients · 2023
    Observational
  15. The role of potential probiotic strainsFrontiers in microbiology · 2023
    Review
  16. Article
  17. Review
  18. Investigating Differential Expressed Genes ofFoods (Basel, Switzerland) · 2022
    Article
  19. Short- term effect of probioticJournal of oral microbiology · 2022
    Article
  20. Extracellular membrane vesicles fromFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Magdalena UrbańskaDepartment of Paediatrics, The Medical University of Warsaw, 01184, Warsaw, Działdowska 1, Poland, magdalena.urb@gmail.com.
Hania Szajewska

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledWe aimed to systematically evaluate evidence on the effectiveness of Lactobacillus reuteri DSM 17938 (L. reuteri) for treating and preventing diseases in infants and children. MEDLINE and the Cochrane Library were searched in December 2013, with no language restrictions, for relevant randomized controlled trials (RCTs) and meta-analyses. The search was updated in April 2014. One systematic review and 14 RCTs met the inclusion criteria. The use of L. reuteri may be considered in the management of acute gastroenteritis as an adjunct to rehydration. There is some evidence that L. reuteri is effective in reducing the incidence of diarrhea in children attending day care centers. There is no evidence of effectiveness of L. reuteri in preventing nosocomial diarrhea in children. The administration of L. reuteri is likely to reduce crying time in infants with infantile colic in exclusively or predominantly exclusively breast-fed infants, but not in formula-fed infants. More studies are needed. Preliminary data suggest that L. reuteri may be effective in the prevention of some functional gastrointestinal disorders, such as colic and regurgitation. This innovative approach needs further evaluation by an independent research team. Preliminary evidence provides a rationale for further assessing the efficacy of L. reuteri for treating functional constipation or functional abdominal pain. However, it is too soon to recommend the routine use of L. reuteri for these conditions. There are no safety concerns with regard to the use of L. reuteri in nonimmunocompromised subjects. There are also data to support the safety of using L. reuteri in preterm infants.

conclusionOur results precisely define current evidence on the effects of the administration of L. reuteri DSM 17938 to the pediatric population.

Indexed as

Limosilactobacillus reuteriAbdominal PainAcute DiseaseChildColicCross InfectionDiarrheaGastroenteritisGastrointestinal DiseasesHumansInfantProbioticsSafety

Identifiers

PMID24819885
PMCPMC4165878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.